An observational study in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Bristol-Myers Squibb · Observational
The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background/concomitant oHCM medications.
The study will include adults in China diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) who initiated mavacamten treatment between 24 October 2024 and 31 March 2026.
Participants must meet all of the following criteria to be included:
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded:
(1) Prior Use of Study Drug: Have any documented history of Mavacamten use (based on medical history records, prescription records, or clinical notes) at any time prior to the Index Date.
Participants who initiate mavacamten as monotherapy and remained on monotherapy throughout follow-up.
Drug: Mavacamten
Participants who initiate mavacamten monotherapy and subsequently added one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications during follow-up.
Drug: Mavacamten
Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and remain on combination therapy throughout follow-up.
Drug: Mavacamten
Participants who initiate mavacamten with one or more background obstructive hypertrophic cardiomyopathy (oHCM) medications and subsequently discontinued all background oHCM medications, resulting in mavacamten monotherapy.
Drug: Mavacamten
Participants whose treatment records indicate multiple treatment changes that could not be classified into the predefined treatment strategy groups.
Drug: Mavacamten
As per product label
Number of participants in each study cohort
Time frame: Baseline and months 1, 2, 3, 6, 9, 12 and 15
Absolute change (mmHg) from baseline in resting peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Absolute change (mmHg) from baseline in post-Valsalva peak left ventricular outflow tract (LVOT) gradient assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Number of participants with at least 1-class improvement from baseline in New York Heart Association (NYHA) functional class
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
New York Heart Association (NYHA) functional class classification as assessed by the treating physician
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Change from baseline in left atrial dimension (LAD) or left atrial volume index (LAVI) assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Change from baseline in interventricular septal thickness (IVST) assessed by transthoracic echocardiography
Time frame: Baseline and at months 1, 2, 3, 6, 9, 12 and 15
Change from baseline in E/e' ratio assessed by transthoracic echocardiography
Time frame: Baseline and months 1, 2, 3, 6, 9, 12 and 15
Prescribed mavacamten dose (mg)
Time frame: Day 1 and months 1, 2, 3, 6, 9, 12 and 15
Prescribed mavacamten maintenance dose (mg) during follow-up
Time frame: Up to 15 months
Number of participants reaching mavacamten maintenance dose
Time frame: Up to 15 months
Number of participants whose prescribed mavacamten dose changed during the observation period
Time frame: Day 1 and and up to 15 months
Time (days) from Index Date to achieving mavacamten maintenance dose
Time frame: Day 1 and up to 15 months
Number of participants that discontinued mavacamten treatment
Time frame: Up to 15 months
Time (days) from Index Date to mavacamten discontinuation
Time frame: Day 1 and up to 15 months
Duration of mavacamten treatment during follow-up
Time frame: Day 1 and up to 15 months
Prior hypertrophic cardiomyopathy (oHCM) medication drug class
Drug class of background oHCM medications, including beta-blockers and calcium channel blockers
Time frame: Baseline and up to 15 months
Prior hypertrophic cardiomyopathy (oHCM) medication dose
Dose of background oHCM medications, including beta-blockers and calcium channel blockers
Time frame: Baseline and up to 15 months
Plan to share: No
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb